Binding and functional properties of doxazosin in the human prostate adenoma and canine brain

The binding and functional properties of doxazosin were characterized in the canine brain and human prostate. 3H‐Doxazosin binding sites were characterized in canine brain and human prostate homogenates using saturation experiments. The binding of 3H‐doxazosin in the canine brain was consistently saturable and of high affinity. The mean equilibrium dissociation constant (Kd) and density (Bmax) of 3H‐doxazosin binding sites in the canine brain were 0.19 nM and 2.17 fmol/mg wet wt, respectively. The binding of 3H‐doxazosin in human prostate homogenates was not consistently linear owing to a relatively high proportion of nonspecific doxazosin binding sites. The mean Kd and Bmax of 3H‐doxazosin binding sites in the prostate determined from the saturation experiments yielding linear Scatchard plots were 0.2 nM and 0.51 fmol/mg wet wt. The pharmacology of doxazosin binding sites was further characterized in the canine brain using competitive binding experiments. The rank order of IC50corr values for norepinephrine, clonidine, yohimbine, terazosin, and prazosin indicated that doxazosin binds selectively to alpha1 and alpha2 adrenergic binding sites. The relative affinity of unlabeled doxazosin for alpha1 and alpha2 binding sites in the human prostate was determined by displacing 125I‐Heat or 3H‐rauwolscine with varying concentrations of unlabeled doxazosin. The affinity of doxazosin for alpha1 binding sites in the prostate adenoma was approximately 100‐fold greater than its affinity for alpha2 binding sites. The potency of doxazosin for inhibiting phenylephrineinduced contractions in the prostate indicated that prostate smooth muscle contraction is mediated by alpha1 adrenoceptors.

[1]  H. Lepor,et al.  Nonoperative management of benign prostatic hyperplasia. , 1989, The Journal of urology.

[2]  H. Lepor,et al.  Contractile properties of human prostate adenomas and the development of infravesical obstruction , 1989, The Prostate.

[3]  H. Lepor,et al.  Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. , 1988, Urology.

[4]  U. Dunzendorfer Clinical experience: symptomatic management of BPH with terazosin. , 1988, Urology.

[5]  H. Lepor,et al.  The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain. , 1988, The Journal of urology.

[6]  J. Lingeman,et al.  Creatinine kinase concentrations and electrocardiographic changes in extracorporeal shock-wave lithotripsy. , 1988, Urology.

[7]  H. Lepor,et al.  Identification and characterization of alpha 1 adrenergic receptors in the canine prostate using [125I]-Heat. , 1987, The Journal of urology.

[8]  R. Kirby,et al.  Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. , 1987, British journal of urology.

[9]  J. Hieble,et al.  In vitro characterization of the alpha-adrenoceptors in human prostate. , 1985, European journal of pharmacology.

[10]  H. Lepor,et al.  Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. , 1984, The Journal of urology.

[11]  D. Klein,et al.  Rat Pineal α1-Adrenoceptors: Identification and Characterization Using [125I]Iodo-2-[β-(4-Hydroxyphenyl)-Ethylaminomethyl]Tetralone , 1984 .

[12]  K. Minneman Binding properties of alpha-1 adrenergic receptors in rat cerebral cortex: similarity to smooth muscle. , 1983, The Journal of pharmacology and experimental therapeutics.

[13]  D. Hoyer,et al.  [125I]BE 2254, a new high affinity radioligand for α1-adrenoceptors , 1981 .

[14]  R. Lefkowitz,et al.  Determination of subtype selectivity of alpha-adrenergic antagonists: comparison of selective and nonselective radioligands. , 1981, Molecular pharmacology.

[15]  P. Greengrass,et al.  Binding characteristics of 3H-prazosin to rat brain α-adrenergic receptors , 1979 .

[16]  S. Meretyk,et al.  A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. , 1978, British journal of urology.

[17]  P. Braithwaite,et al.  Alpha‐adrenergic blockers in prostatism , 1977, The British journal of surgery.

[18]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.